Please type a plus sign (+) inside this box

PTO/SB/05 (11-00) Approved for use through 10/31/2002, OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

### UTILITY PATENT APPLICATION TRANSMITTAL

Attorn	ney Docket No.	A080 US			
First I	nventor	Browning			
Title	BAFF R	BAFF RECEPTOR (BCMA), An			
Express Mail Lahel No.		EL475127434US			

(Only for new nonprovisional applications under 37 CFR 1.53(b)) Assistant Commissioner for Patents U APPLICATION ELEMENTS ADDRESS TO: Box Patent Application See MPEP chapter 600 concerning utility patent application contents. Washington, DC 20231 Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or (Submit an original and a duplicate for fee processing) Computer Program (Appendix) Applicant claims small entity status. 8. Nucleotide and/or Amino Acid Sequence Submission See 37 CFR 1.27. (if applicable, all necessary) Specification [Total Pages (preferred arrangement set forth below) 3. **X** a. X Computer Readable Form (CRF) - Descriptive title of the invention b. Specification Sequence Listing on: - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D CD-ROM or CD-R (2 copies); or i. 🔲 - Reference to sequence listing, a table, i i. 🗶 or a computer program listing appendix
- Background of the Invention c. X Statements verifying identity of above copies - Brief Summary of the Invention ACCOMPANYING APPLICATION PARTS - Brief Description of the Drawings (if filed) - Detailed Description Assignment Papers (cover sheet & document(s)) - Claim(s) 37 CFR 3.73(b) Statement Power of - Abstract of the Disclosure 10. (when there is an assignee) Attorney 4. Total Sheets 19 English Translation Document (if applicable) Copies of IDS Information Disclosure 5. Oath or Declaration [ Total Pages 12. Citations Statement (IDS)/PTO-1449 Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) (for continuation/divisional with Box 18 completed) Preliminary Amendment Return Receipt Postcard (MPEP 503) b. (Should be specifically itemized) Certified Copy of Priority Document(s) (if foreign priority is claimed) **DELETION OF INVENTOR(S)** Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR Request and Certification under 35 U.S.C. 122 1.63(d)(2) and 1.33(b). (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. Application Data Sheet. See 37 CFR 1.76 17. Other: 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: PCT/US00/22507 Continuation X Divisional Continuation-in-part (CIP) of prior application No.: Prior application information: Group Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS Customer Number or Bar Code Label Correspondence address below (insert Customer No. or Attach par code label here) Name Timothy P. Linkkila BIOGEN, INC. 14 Cambridge Center Address City State Cambridge Zip Code MA 02142 Country **USA** Telephone (617) 679-3795 Fax (617) 679-2838 Timothy P. Linkkila Name (Print/Type) 40,702 Registration No. (Attorney/Agent) Signature

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



:=

al.

J

PTO/SB/17 (10-01)
Approved for use through 10/31/2002 OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid QMB control number.

# **FEE TRANSMITTAL** for FY 2002

Patent fees are subject to annual revision.

1,430 **TOTAL AMOUNT OF PAYMENT** (\$)

Complete if Known					
Application Number					
Filing Date					
First Named Inventor	Browning				
Examiner Name					
Group Art Unit					
Attorney Docket No.	A080 US CIP				

METHOD OF PAYMENT				FE	E CALCULATION (continued)			
1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:			ES					
indicated fees and credit any overpayments to		Large Small						
Account   02-2327	Fee	Entity Fee		Entity Fee		Fee Paid		
Number Deposit	Code		Code		Fee Description	reeraiu		
Account	105	130	205	65	Surcharge - late filing fee or oath			
Name Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	127	50	227		Surcharge - late provisional filing fee or cover sheet			
Applicant claims small entity status	139	130	139	130	Non-English specification			
See 37 CFR 1 27	147 2	2,520	147	2,520	For filing a request for ex parte reexamination			
2. Payment Enclosed:  Check Credit card Money Other	112	920*	112	920*	Requesting publication of SIR prior to Examiner action			
FEE CALCULATION	113 1	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action						
1. BASIC FILING FEE	115	110	215	55	Extension for reply within first month			
Large Entity Small Entity	116	400	216	200	Extension for reply within second month			
Fee Fee Fee Fee Description	117	920	217	460	Extension for reply within third month			
00de (v) 00de (v)	118 1	1,440	218	720	Extension for reply within fourth month			
101 740 201 370 Utility filing fee 740	128 1	1,960	228	980	Extension for reply within fifth month			
	119	320	219	160	Notice of Appeal			
107 510 207 255 Plant filing fee 108 740 208 370 Reissue filing fee	120	320	220	160	Filing a brief in support of an appeal			
114 160 214 80 Provisional filing fee	121	280	221	140	Request for oral hearing			
	138	1,510	138	1,510	Petition to institute a public use proceeding			
<b>SUBTOTAL (1)</b> (\$) 740	140	110	240	55	Petition to revive - unavoidable			
2. EXTRA CLAIM FEES	141 1	1,280	241	640	Petition to revive - unintentional			
Fee from Extra Claims below Fee Paid			242	640	Utility issue fee (or reissue)			
Total Claims 21 -20** = 1 X 18 = 18	143	460	243	230	Design issue fee			
Independent	144	620	244	310	Plant issue fee			
Multiple Dependent = 0	122	130	122	130	Petitions to the Commissioner			
	123	50	123	50	Processing fee under 37 CFR 1.17(q)			
Large Entity Small Entity	126	180	126	180	Submission of Information Disclosure Stmt			
Fee Fee Fee Fee Description Code (\$) Code (\$)	581	40	581	40	Recording each patent assignment per			
103 18 203 9 Claims in excess of 20					property (times number of properties)			
102 84 202 42 Independent claims in excess of 3	146	740	246	370	Filing a submission after final rejection (37 CFR § 1 129(a))			
104 280 204 140 Multiple dependent claim, if not paid  109 84 209 42 ** Reissue independent claims	149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))			
over original patent	1							
110 18 210 9 ** Reissue claims in excess of 20	179	740	279	370	Request for Continued Examination (RCE)			
and over original patent	169	900	169	900	Request for expedited examination of a design application			
SUBTOTAL (2) (\$) 690	Other	fee (s	pecify	r)				
00B101A2 (2)	1				Fee Paid SUBTOTAL (3)	0		
**or number previously paid, if greater; For Reissues, see above	Real	rcea p	y bas	ic riiing	Fee Paid SUBTOTAL (3) (\$)			

SUBMITTED BY	ED BY Complete (if applicable)					
Name (Print/Type)	Timothy P. Linkkila	Registration No. (Attorney/Agent)	40,702	Telephone	(617) 679-3795	
Signature	Thinty P. Aik	bila.		Date	2/15/02	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement This form is estimated to take 0.2 hours to complete Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patents, Washington, DC 20231.

(**E**  Applicant: Browning, et al.
Serial No.: Not Assigned yet

Filing Date: Herewith

For: Baff Receptor (BCMA), An Immunoregulatory Agent

### CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence:
Utility Patent Application Transmittal, Fee Transmittal, Statement regarding Sequence
Listing, Paper and Electronic copies of Sequence, Utility Application (41 pages) and 19
sheets of drawings, authorization to charge our deposit account
is being deposited with the United States Postal Service under 37 CFR 1.10 as Express Mail
Label No. <u>EL475127434US</u> in an envelope addressed to:
Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231
<b>3</b> ,
on February 15, 2002
Date Patricu Hofretter
Patricia Hofstetter

# LT

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Browning, et al.

Serial No.:

Not assigned yet

Filing Date:

Herewith

For:

Baff Receptor (BCMA), An Immunoregulatory Agent

### CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Post Office via Express Mail Label EL475127434US addressed to BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: February 15, 2002 Signature: Vafria Highthe

## STATEMENT REGARDING SEQUENCE LISTING

Applicant hereby submits a diskette containing a machine-readable copy of the Sequence Listing done in FastSEQ 4.0.

The contents of the paper and computer readable copies are the same and, include no new matter, as required by 37 C.F.R. 1.821 (e). The sequences on the diskette and on the paper listing are identical to the sequences submitted in the application as filed.

Please charge our deposit account 02-2327 for any deficiencies.

Respectfully submitted,

Date: 415/02

Timothy P. Linkkha Reg. No. 40,702

BIOGEN, INC.

14 Cambridge Center Cambridge, MA 02142

(617) 679-3795

#9554